Opexa Therapeutics Inc (NASDAQ: OPXA)
Opexa Therapeutics is a clinical stage biopharma company that proved today that it’s getting closer and closer to a product launch. At the 2015 Microcap Conference, President and CEO of OPXA, Neil K. Warma gave a presentation that clearly excited investors. I took the time to listen to the presentation myself, and I can see why investors are so excited. Today, we’ll take a look at the highlights of the presentation and talk about what it means for the future of OPXA as a company and an investment.
What You Need To Know From The OPXA Presentation
The presentation today showed that Opexa Therapeutics is a strong company with strong product candidates. The first point that really stood out to me is that OPXA has absolutely no debt. As a clinical stage company with no treatments yet approved, operating without debt is a great feat! Overall, the finances looked great.
Another thing that really jumped out was the company’s progression with regard to its pipeline. First, we learned about Tcelna; a treatment being tested for Secondary Progressive Multiple Sclerosis and the company’s flagship candidate at the moment. The news was great. The treatment is currently in Phase 2b and has an excellent potential market value and very little competition. Also in the pipeline section, the company announced the addition of a new treatment that looks promising for neuromyelitis optica. The important thing here is that neuromyelitis optica is an ailment that currently has no approved treatments; making OPX 212, the new candidate a candidate for the orphan indication.
Validation also played a major role in the overall positive reaction investors had to the presentation. In the presentation, we learned that there’s a potential partnership in the works with Merck Serono that will be based around Tcelna if it comes to fruition. Also, Tcelna has received Fast Track Designation from the FDA for the approval of the treatment.
Perhaps the most interesting part of the presentation was when the Opexa’s CEO discussed the technology they’ve developed that allows them to treat autoimmune disease patients with unique treatments designed to target each patient’s unique needs.
What We Can Expect To See From Opexa Therapeutics Moving Forward
Moving forward, I’m expecting to see great things from Opexa Therapeutics. The presentation today was a clear sign that Opexa Therapeutics is under incredible management. The plan for the company is very clear and they’ve been incredibly transparent with their finances; which might I add, are incredible for their stage! Then, we get to the pipeline. With Tcelna going through the fast track with the FDA and the promising signs of a partnership with Merck Serono, things are looking like the company will be headed for profits in no time. Also, the team at Opexa has a clear talent with regard to medical innovation; which I’m sure will lead to more good news in the long run. With all of that said, get ready for more gains both in the short term and long term view.
What Do You Think?
Where do you think OPXA is headed and why? Let us know in the comments below!
